Quick Answer
Xenetic Biosciences, Inc. reported Operating Income of -$2.83 million for fiscal year 2025.
Xenetic Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$2.83M | +32.6% |
| 2024 | -$4.20M | +6.9% |
| 2023 | -$4.52M | +32.8% |
| 2022 | -$6.72M | -16.9% |
| 2021 | -$5.75M | +58.8% |
| 2020 | -$13.94M | -8.2% |
| 2019 | -$12.89M | -77.1% |
| 2018 | -$7.28M | -103.9% |
| 2017 | -$3.57M | +92.5% |
| 2016 | -$47.43M | -382.9% |
| 2015 | -$9.82M | +24.0% |
| 2014 | -$12.92M | -51.2% |
| 2013 | -$8.55M | -12938.0% |
| 2013 | -$65.6K | +43.8% |
| 2012 | -$116.7K | -1481.8% |
| 2011 | -$7.4K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$544.7K | -9.1% | +24.8% |
| June 30, 2025 | -$724.4K | +45.8% | +23.1% |
| March 31, 2025 | -$942.4K | +25.7% | -88.7% |
| September 30, 2024 | -$499.5K | +56.4% | +62.7% |
| June 30, 2024 | -$1.34M | -11.6% | -5.4% |
| March 31, 2024 | -$1.27M | -38.6% | -10.6% |
| September 30, 2023 | -$1.15M | -35.3% | +4.3% |
| June 30, 2023 | -$1.20M | +55.4% | -30.9% |
- Xenetic Biosciences, Inc. showed an increase of +32.6% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Xenetic Biosciences, Inc.’s operating income has declined by 38335.0% (from -$7.4 thousand to -$2.83 million).
- The most recent figure is from Xenetic Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: